PMID- 29675688
OWN - NLM
STAT- MEDLINE
DCOM- 20190718
LR  - 20200225
IS  - 2095-0225 (Electronic)
IS  - 2095-0217 (Linking)
VI  - 13
IP  - 1
DP  - 2019 Feb
TI  - Everyone has a donor: contribution of the Chinese experience to global practice 
      of haploidentical hematopoietic stem cell transplantation.
PG  - 45-56
LID - 10.1007/s11684-017-0595-7 [doi]
AB  - Human leukocyte antigen (HLA)-matched donors for hematopoietic stem cell 
      transplantation (HSCT) have long been scarce in China. Haploidentical (haplo) 
      donors are available for the vast majority of patients, but toxicity has limited 
      this approach. Three new approaches for haplo-HSCT originated from Italy, China, 
      and USA in 1990 and have been developed to world-renowned system up to now. The 
      Chinese approach have been greatly improved by implementing new individualized 
      conditioning regimens, donor selection based on non-HLA systems, risk-directed 
      strategies for graft-versus-host disease and relapse, and infection management. 
      Haplo-HSCT has exhibited similar efficacy to HLA-matched HSCT and has gradually 
      become the predominant donor source and the first alternative donor choice for 
      allo-HSCT in China. Registry-based analyses and multicenter studies adhering to 
      international standards facilitated the transformation of the unique Chinese 
      experience into an inspiration for the refinement of global practice. This review 
      will focus on how the new era in which "everyone has a donor" will become a 
      reality in China.
FAU - Lv, Meng
AU  - Lv M
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      100044, China.
FAU - Chang, Yingjun
AU  - Chang Y
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      100044, China.
FAU - Huang, Xiaojun
AU  - Huang X
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 
      100044, China. huangxiaojun@bjmu.edu.cn.
AD  - Peking-Tsinghua Center for Life Sciences, Beijing, 100044, China. 
      huangxiaojun@bjmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180419
PL  - China
TA  - Front Med
JT  - Frontiers of medicine
JID - 101549428
RN  - 0 (HLA Antigens)
SB  - IM
MH  - China
MH  - Donor Selection
MH  - Graft vs Host Disease/immunology
MH  - HLA Antigens/*immunology
MH  - Hematologic Neoplasms/immunology/*surgery
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Histocompatibility
MH  - Histocompatibility Testing
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Transplantation Conditioning
OTO - NOTNLM
OT  - conditioning
OT  - donor selection
OT  - graft-versus-host disease
OT  - haploidentical hematopoietic stem cell transplantation
OT  - infection
OT  - relapse
EDAT- 2018/04/21 06:00
MHDA- 2019/07/19 06:00
CRDT- 2018/04/21 06:00
PHST- 2017/04/14 00:00 [received]
PHST- 2017/09/30 00:00 [accepted]
PHST- 2018/04/21 06:00 [pubmed]
PHST- 2019/07/19 06:00 [medline]
PHST- 2018/04/21 06:00 [entrez]
AID - 10.1007/s11684-017-0595-7 [pii]
AID - 10.1007/s11684-017-0595-7 [doi]
PST - ppublish
SO  - Front Med. 2019 Feb;13(1):45-56. doi: 10.1007/s11684-017-0595-7. Epub 2018 Apr 
      19.